Growth hormone treatment in a girl with Prader Willi syndrome.
Prader Willi syndrome (PWS) is a rare endocrine-metabolic disorder that is characterised by neonatal hypotonia, hyperphagia, marked obesity, short stature, hypogonadism and behavioural problems. 7-20% percent of these children develop diabetes mellitus. A large number of individuals with PWS show growth hormone (GH) deficiency. Recent studies indicate beneficial effects of GH replacement therapy not only for their linear growth but also for correction of metabolic dysfunction. In the present communication this article details about the therapeutic outcome in a girl with PWS who received recombinant growth hormone (rGH), Genotropin. Some carry-over therapeutic benefits have been observed even after discontinuation of rGH.
Pandey
S N
SN
Bhavan's SPARC Center for Disorders of Growth & Puberty 13th N.S. Road, JVPD, Mumbai-400 049. bhaspa@bom5.vsnl.net.in
Vaidya
R A
RA
Irani
A
A
D000293:Adolescent; D005260:Female; D005951:Glucose Tolerance Test; D006128:Growth / Q000187:drug effects; D019382:Human Growth Hormone / Q000097:blood / Q000627:therapeutic use*; D006801:Humans; D010908:Pituitary Hormones, Anterior / Q000097:blood; D011218:Prader-Willi Syndrome / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome
D010908:Pituitary Hormones, Anterior; D011994:Recombinant Proteins; D019382:Human Growth Hormone